CN107703312A - The protein marker and method of examination medicine anaphylactoid reaction sensitive group - Google Patents
The protein marker and method of examination medicine anaphylactoid reaction sensitive group Download PDFInfo
- Publication number
- CN107703312A CN107703312A CN201711130601.4A CN201711130601A CN107703312A CN 107703312 A CN107703312 A CN 107703312A CN 201711130601 A CN201711130601 A CN 201711130601A CN 107703312 A CN107703312 A CN 107703312A
- Authority
- CN
- China
- Prior art keywords
- mrgprx2
- peripheral blood
- albumen
- anaphylactoid reaction
- sensitive group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
Abstract
The invention provides using MRGPRX2 albumen as the protein marker for medicine anaphylactoid reaction sensitive group examination and application.The present invention has found that the relative expression quantity of MRGPRX2 albumen in peripheral blood has correlation with the medicine anaphylactoid reaction sensitiveness of tester by studying, can be using MRGPRX2 albumen as the protein marker for medicine anaphylactoid reaction sensitive group examination；The risk of anaphylactoid reaction occurs during medication using the relative expression quantity of MRGPRX2 albumen as evaluation patient, it is significant to the security of clinically direction of medication usage.The method of examination medicine anaphylactoid reaction sensitive group provided by the invention, for patient's anaphylactoid reaction occurrence risk examination, with very high Sensitivity and Specificity, and due to being detected using the peripheral blood clinically most easily gathered, it is easy to use, suitable for large-scale crowd examination before patient medication, promote anaphylactoid reaction that the discovery in advance of crowd easily occurs, improve the security of medication.
Description
Technical field
The present invention relates to technical field of molecular biology, more particularly to a kind of examination medicine anaphylactoid reaction sensitive group
Protein marker and method.
Background technology
Medicine, which causes allergic reaction, is broadly divided into I types (anaphylactic type), II types (cell toxicant type), type III (immune complex
Type), (delayed) allergic reaction of IV types and anaphylactoid reaction.The clinical symptoms of anaphylactoid reaction are similar with allergic reaction.But its
The mechanism of reaction and type i allergic reaction simultaneously differ.After medicine enters in vivo, mast cell release content can be directly resulted in
Thing, allergic reaction is triggered, and clinical symptoms are serious.Anaphylactic shock betides the individual that only a few receives therapeutic dose medicine,
There is no sensitization process, patients serum IgE concentration also has no rise, but shows as typical anaphylactic type symptom, therefore
Be otherwise known as false drug allergy.Anaphylactoid reaction is unrelated with antigen specific immune reaction, in such medicine of first contacts
Shi Fasheng, and have certain correlation with dosage, injection speed., not only can quilt as the mast cell of allergy main effects device
Specific IgE adheres to and activating causes degranulation, causes I type allergy, also can be by a variety of secretagogues matter such as inflammatory factor, medicine
Directly activation causes cell degranulation, causes clinical common anaphylactoid reaction, make patient occur skin lesion symptom show it is red
Spot, nettle rash, oedema etc., severe patient can cause the symptoms such as asthma, shock.Mechanism caused by anaphylactoid reaction is not yet complete at present
Understanding, histamine release of mast cell may be directly stimulated with sensitizer, or directly by the anaphylatoxin such as C5a, C3a, C4a and fertilizer
The mast cell degranulation that maxicell specific membrane receptor mediates after combining is relevant.
The clinical manifestation of anaphylactoid reaction be local skin symptom for example the blood vessel dilatation of Head And Face, chest and four limbs, erythema,
Oedema, conjunctival congestion；Gastrointestinal symptom such as salivation, nausea,vomiting,diarrhea, apocleisis；Respiratory circulatory system symptom such as chest
Vexed, palpitaition, blood pressure rise, expiratory dyspnea, serious occurs respiratory and circulatory failure, causes patient's shock, death.Its symptom is special
Point is relevant with the speed of medical intravenous injection, and injection speed is faster, and the burst size of histamine is bigger, and body reaction is more serious, i.e., low
Dosage, low concentration, can without or only there are light symptoms；Heavy dose of, high concentration can induce serious adverse drug reaction.But
The reaction symptom of body can gradually weaken with repeat administration or even voluntarily disappear, and allergic reaction does not have this feature then.
The occurrence frequency in clinic constantly raises in recent years, the 77% of acute allergic reaction is accounted for, in traditional Chinese medicine
In caused anaphylactic shock, about 3/4 belongs to anaphylactoid reaction, because its clinical harmfulness is big, has become the focus of concern.
But at present clinically not monitor anaphylactoid reaction respective standard, have more in advance detection patient's class allergy it is anti-
Answer the correlative study of risk.There is the problem of various in conventional mark histamine, trypsinlike enzyme and IgE, and uncomfortable
For clinical detection anaphylactoid reaction.
Research is found：G-protein of the class allergic stimulated thing first on active cell film, and then activated protein kinase C and Ca2+It is logical
Road, endoplasmic reticulum is set to discharge Ca2+Into intracellular.Along with intracellular Ca2+Concentration increase, mast cell and basophilic granulocyte
Interior granular vesicle is mobile to endochylema film and discharges Biomedia, so as to trigger anaphylactoid reaction.《Nature》Etc. a variety of authoritys
A large amount of reports of magazine confirm, the G-protein that class allergic stimulated thing is activated be MRGPRS (MAS-Related G Protein-
Coupled Receptors), this receptor mediating mast cell can directly activate independent of IgE, induce mast cell degranulation.
This receptoroid each kind, tissue and organ expression type and differ：Wherein MRGPRX2 tables in the mast cell of people source
Reach；This receptor extracellular region is induction zone, specificity it is not high, when it is extracellular by degranulation polypeptide, Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2, Compound 48/80, β-
After the activation of many kinds of substance such as alexin, the triggering of intracellular region signal, cause the particulate matter such as mast cells activation, release histamine, thorn
Cell paracrine is swashed, so as to have influence on peripheral cell.MRGPRX2 is that many small-molecule drugs cause class allergy, false allergy
Action target spot.Therefore by the analysis to MRGPRX2 gene copy numbers, so as to deduce MrgprX2 acceptors in different patients
Expression quantity, help to evaluate patient the risk of anaphylactoid reaction occur during medication, to the peace of clinically direction of medication usage
Full property is significant.
The content of the invention
It is an object of the invention to provide a kind of protein marker and method of examination medicine anaphylactoid reaction sensitive group,
And application of the protein marker in examination medicine anaphylactoid reaction sensitive group, so as to which detecting patient in advance occurs class
Anaphylactoid risk, guidance is provided for data for clinical drug use.
The present invention is to be achieved through the following technical solutions：
A kind of protein marker for medicine anaphylactoid reaction sensitive group examination, the protein marker are
MRGPRX2 albumen.
Application of the MRGPRX2 albumen in examination medicine anaphylactoid reaction sensitive group.
A kind of method of examination medicine anaphylactoid reaction sensitive group, including step：
1) tester's peripheral blood is taken；
2) with the expression quantity of MRGPRX2 albumen in ELASA kits detection peripheral blood；
3) judge whether tester belongs to medicine anaphylactoid reaction sensitive group；
If the expression quantity of MRGPRX2 albumen is not more than 14.43ng/mL, it is quick that tester is not belonging to medicine anaphylactoid reaction
Touching group；If the expression quantity of MRGPRX2 albumen is more than 14.43ng/mL and is less than 20.58ng/mL, tester is uncertain to be belonged to
Medicine anaphylactoid reaction sensitive group by other method, it is necessary to further confirm that；If the expression quantity of MRGPRX2 albumen is not less than
20.58ng/mL, then tester belong to medicine anaphylactoid reaction sensitive group；
Wherein, the expression quantity of MRGPRX2 albumen is the ratio of MRGPRX2 albumen qualities and peripheral blood volume in peripheral blood.
A kind of method of examination medicine anaphylactoid reaction sensitive group, including step：
1) tester's peripheral blood is taken；
2) with the expression quantity of MRGPRX2 albumen in ELASA kits detection peripheral blood；
3) judge whether tester belongs to medicine anaphylactoid reaction sensitive group；
If the peripheral blood MRGPRX2 expressing quantities of tester are less than 20.58ng/mL, it is not belonging to medicine class allergy
React sensitive group；If the peripheral blood MRGPRX2 expressing quantities of tester are not less than 20.58ng/mL, it belongs to medicine class
Allergic reaction sensitive group；
Wherein, the expression quantity of MRGPRX2 albumen is the ratio of MRGPRX2 albumen qualities and peripheral blood volume in peripheral blood.
A kind of method of examination medicine anaphylactoid reaction sensitive group, including step：
1) tester's peripheral blood is taken；
2) with the expression quantity of MRGPRX2 albumen in ELASA kits detection peripheral blood；
3) judge whether tester belongs to medicine anaphylactoid reaction sensitive group；
If the peripheral blood MRGPRX2 expressing quantities of tester are not more than 14.43ng/mL, it is not belonging to medicine class mistake
Quick reaction sensitive group；If the peripheral blood MRGPRX2 expressing quantities of tester are more than 14.43ng/mL, it belongs to medicine class
Allergic reaction sensitive group；
Wherein, the expression quantity of MRGPRX2 albumen is the ratio of MRGPRX2 albumen qualities and peripheral blood volume in peripheral blood.
Preferably, in step 1), the amount of peripheral blood is 1.5~2.0mL.
Compared with prior art, the present invention has technique effect beneficial below：
The invention provides using MRGPRX2 albumen as the protein labeling for medicine anaphylactoid reaction sensitive group examination
Thing and application.It is of the invention to be found by studying, the relative expression quantity of MRGPRX2 albumen and the medicine class of tester in peripheral blood
Allergic reaction sensitiveness has correlation, therefore, can be using MRGPRX2 albumen as being used for medicine anaphylactoid reaction sensitive group
The protein marker of examination；Class allergy occurs during medication using the relative expression quantity of MRGPRX2 albumen as evaluation patient
The risk of reaction, it is significant to the security of clinically direction of medication usage.
The method of examination medicine anaphylactoid reaction sensitive group provided by the invention, wind occurs for patient's anaphylactoid reaction
Dangerous examination, there is very high Sensitivity and Specificity, and due to being detected using the peripheral blood clinically most easily gathered, make
With conveniently, suitable for large-scale crowd examination before patient medication, promote anaphylactoid reaction that the discovery in advance of crowd easily occurs, improve and use
The security of medicine.
Brief description of the drawings
Fig. 1-1 is MRGPRX2 receptor protein Western Blot testing results, and wherein High groups represent clinically to occur
The crowd of anaphylactoid reaction, Low groups represent the control group crowd for not occurring anaphylactoid reaction.
Fig. 1-2 is Fig. 1-1 quantification result, from Western Blot testing results, two groups of crowd MRGPRX2 by
Body protein expression has otherness, and crowd's (high) receptor protein amount of anaphylactoid reaction occurred apparently higher than not occurring
The control group crowd (low) (n=15, P ＜ 0.01) of anaphylactoid reaction.
Fig. 2 is MRGPRX2 receptor protein ELISA kit testing results, and wherein Positive groups represent clinically to occur
The crowd of anaphylactoid reaction, Negative groups represent the control group crowd for not occurring anaphylactoid reaction, can by ELISA testing results
Know, two groups of crowd MRGPRX2 receptor proteins expression have otherness, and crowd's receptor protein amount of anaphylactoid reaction occurred
Apparently higher than the control group crowd (n=15, P ＜ 0.001) for not occurring anaphylactoid reaction.
Embodiment
With reference to specific embodiment, the present invention is described in further detail, it is described be explanation of the invention and
It is not to limit.
The present invention compares normal patient and medicine class mistake occurred by the total protein expression situation of quantitative analysis peripheral blood
The differential expression of peripheral blood MRGPRX2 albumen, calculates MRGPRX2 albumen outside Different Individual in quick reaction two groups of samples of patient
The protein signal of differential expression (expressing quantity is higher than average level or less than average level) occurs in all blood, i.e., in peripheral blood
The expression signal of MRGPRX2 characteristic proteins (biomarker).Albumen in person under inspection's peripheral blood is detected using ELASA standard measures
The expression quantity of mark differentiates whether person under inspection belongs to medicine anaphylactoid reaction sensitive group；If subject belongs to medicine class allergy
Sensitive group is reacted, then anaphylactoid reaction can occur after medication for subject and corresponding risk probability is big, and clinic is instructed with this
Medication.
Embodiment 1
The determination of characteristic protein mark expression quantity in normal population, comprises the following steps：
1) peripheral blood sample of 15 testers that anaphylactoid reaction does not occur clinically, each sample collection are collected
1.5-2mL peripheral blood.
2) finished product ELASA kits (Human Mas-Related G-Protein Coupled Receptor are utilized
Member X2(MRGPRX2)ELISA Kit)(Cat.No:MBS9333336) method, the expression quantity of MRGPRX2 albumen is detected.
3) in 15 samples, the maximum of MRGPRX2 expressing quantities is 14.43ng/mL, minimum value 12.15ng/
mL。
The determination of the characteristic protein mark expression quantity in allergic human population of embodiment 2, comprises the following steps：
1) 15 peripheral blood samples for clinically determining that the tester of anaphylactoid reaction occurs, each sample collection are collected
1.5-2mL peripheral blood.
2) finished product ELASA kits (Human Mas-Related G-Protein Coupled Receptor are utilized
Member X2(MRGPRX2)ELISA Kit)(Cat.No:MBS9333336) method, the expression quantity of MRGPRX2 albumen is detected.
3) in 15 samples, the maximum of MRGPRX2 expressing quantities is 25.65ng/mL, minimum value 20.58ng/
mL。
According to the displaying of the measurement result of embodiment 1 and embodiment 2 in fig. 2, it can be evident that, sent out according to Fig. 2
The peripheral blood MRGPRX2 expressing quantities of the tester (Positive) of raw anaphylactoid reaction are anti-apparently higher than class allergy does not occur
The tester (Negative) answered, do not occur simultaneously between the peripheral blood MRGPRX2 expressing quantities of two groups of testers.Examined using t
Test, clearly there can be significant difference (P ＜ 0.001) in the peripheral blood MRGPRX2 expressing quantities of two groups of testers.Therefore,
We can very clearly, if tester belongs to medicine anaphylactoid reaction sensitive group, its peripheral blood MRGPRX2 expressing quantities
Raised compared to non-drug anaphylactoid reaction sensitive group.
Based on this trend, it may be determined that when the peripheral blood MRGPRX2 expressing quantities of tester are not less than 20.58ng/
During mL, it belongs to medicine anaphylactoid reaction sensitive group；If the peripheral blood MRGPRX2 expressing quantities of tester are not more than
During 14.43ng/mL, then it is not belonging to medicine anaphylactoid reaction sensitive group.Certainly, if the peripheral blood MRGPRX2 eggs of tester
White expression quantity is more than 14.43ng/mL and is less than 20.58ng/mL, then the tester needs to be confirmed whether by other examination means
Belong to medicine anaphylactoid reaction sensitive group.Using this determination methods, it can clearly go out whether tester belongs to medicine class mistake
Quick reaction sensitive group, is clearly instructed to be provided for clinical application.
3) statistical method is utilized, the people for contrasting allergic human population and not occurring allergy removes middle MRGPRX2 expressing quantities,
P ＜ 0.001, there is otherness.
4) statistical method is utilized, MRGPRX2 expressing quantities in two class crowds is contrasted, finds out MRGPRX2 albumen tables
Up to the otherness of amount.
Meanwhile in 15 do not occur the patient of anaphylactoid reaction, the maximum of its MRGPRX2 expressing quantity is
14.43ng/mL；And in the patient of 15 generation anaphylactoid reactions, the minimum value of its MRGPRX2 expressing quantity is 20.58ng/
M, 50% is higher by than 14.43ng/mL, very huge difference be present；
Therefore, we can be according to specific purposes, then construct such as the following two kinds model：
A) if the peripheral blood MRGPRX2 expressing quantities of tester are less than 20.58ng/mL, it is not belonging to medicine class mistake
Quick reaction sensitive group；If the peripheral blood MRGPRX2 expressing quantities of tester are not less than 20.58ng/mL, it belongs to medicine
Anaphylactoid reaction sensitive group.According to this judgment models, the medicine anaphylactoid reaction sensitive group that examination personnel filter out has
There is very high accuracy, that is, judge that the tester's maximum probability for belonging to medicine anaphylactoid reaction sensitive group belongs to the colony, its
It is easy to medical personnel and researcher to carry out the very strong treatment and research work of specific aim.According to the model, partly to medicine class
The sensitive tester of allergic reaction is judged as being not belonging to medicine anaphylactoid reaction sensitive group, and therefore, it is not suitable for as seeking
Look for the model of non-drug anaphylactoid reaction sensitive group.
B) if the peripheral blood MRGPRX2 expressing quantities of tester are not more than 14.43ng/mL, it is not belonging to medicine class
Allergic reaction sensitive group；If the peripheral blood MRGPRX2 expressing quantities of tester are more than 14.43ng/mL, it belongs to medicine
Anaphylactoid reaction sensitive group.According to this judgment models, non-drug anaphylactoid reaction sensitive group that examination personnel filter out
With very high accuracy, that is, judge that the tester's maximum probability for belonging to non-drug anaphylactoid reaction sensitive group belongs to the group
Body, it is easy to medical personnel and researcher to carry out the very strong treatment and research work of specific aim, and the tester that avoids worrying is to medicine
Species allergic reaction is sensitive and can not select optimum treatment scheme.According to the model, part non-drug anaphylactoid reaction is sensitive
Tester is judged as belonging to medicine anaphylactoid reaction sensitive group, and therefore, it is not suitable for as searching medicine anaphylactoid reaction
The model of sensitive group.
Embodiment 3
Verify characteristic protein mark MRGPRX2 albumen in allergic human population and normal population using Western-Blot
Expression quantity, comprise the following steps：
1) total protein in allergic human population and normal population blood is extracted, with BCA protein quantifications kit (the rich biology of shellfish
BB-3401-500T) method measure albumen applied sample amount.
2) Western-Blot SDS-PAGE Kit (PIONEER are utilized；WBO1) method detection allergic human population and normal population
The relative expression quantity of middle MRGPRX2 albumen.Experimental results show is in Fig. 1-1 and Fig. 1-2, especially in accordance with Fig. 1-2 result
, it is apparent that relative to normal population (low), MRGPRX2 albumen is in periphery in medicine anaphylactoid reaction crowd (high)
Relative expression quantity in blood substantially increases, and this is consistent with ELASA experimental results.
Verify characteristic protein mark MRGPRX2 albumen in allergic human population and normal population using Western-Blot
Expression analysis, by testing and analyzing result to MRGPRX2 expressing quantities in normal population and allergic human population, allergic human population's
MRGPRX2 expressing quantities are above the MRGPRX2 expressing quantities of normal population, have significant otherness, with ELASA methods
Comparing result has certain correlation, further demonstrates the method examination medicine class mistake using MRGPRX2 protein markers
The feasibility of quick reaction sensitive group.Therefore the method for MRGPRX2 protein markers can be utilized to differentiate whether person under inspection uses again
Anaphylactoid reaction and corresponding risk probability can occur after medicine, instruct clinical application.
Claims (6)
- A kind of 1. protein marker for medicine anaphylactoid reaction sensitive group examination, it is characterised in that the protein labeling Thing is MRGPRX2 albumen.
- Application of the 2.MRGPRX2 albumen in examination medicine anaphylactoid reaction sensitive group.
- A kind of 3. method of examination medicine anaphylactoid reaction sensitive group, it is characterised in that including step：1) tester's peripheral blood is taken；2) with the expression quantity of MRGPRX2 albumen in ELASA kits detection peripheral blood；3) judge whether tester belongs to medicine anaphylactoid reaction sensitive group；If the expression quantity of MRGPRX2 albumen is not more than 14.43ng/mL, tester is not belonging to medicine anaphylactoid reaction sensitivity people Group；If the expression quantity of MRGPRX2 albumen is more than 14.43ng/mL and is less than 20.58ng/mL, tester is uncertain to belong to medicine Anaphylactoid reaction sensitive group by other method, it is necessary to further confirm that；If the expression quantity of MRGPRX2 albumen is not less than 20.58ng/mL, then tester belong to medicine anaphylactoid reaction sensitive group；Wherein, the expression quantity of MRGPRX2 albumen is the ratio of MRGPRX2 albumen qualities and peripheral blood volume in peripheral blood.
- A kind of 4. method of examination medicine anaphylactoid reaction sensitive group, it is characterised in that including step：1) tester's peripheral blood is taken；2) with the expression quantity of MRGPRX2 albumen in ELASA kits detection peripheral blood；3) judge whether tester belongs to medicine anaphylactoid reaction sensitive group；If the peripheral blood MRGPRX2 expressing quantities of tester are less than 20.58ng/mL, it is not belonging to medicine anaphylactoid reaction Sensitive group；If the peripheral blood MRGPRX2 expressing quantities of tester are not less than 20.58ng/mL, it belongs to medicine class allergy React sensitive group；Wherein, the expression quantity of MRGPRX2 albumen is the ratio of MRGPRX2 albumen qualities and peripheral blood volume in peripheral blood.
- A kind of 5. method of examination medicine anaphylactoid reaction sensitive group, it is characterised in that including step：1) tester's peripheral blood is taken；2) with the expression quantity of MRGPRX2 albumen in ELASA kits detection peripheral blood；3) judge whether tester belongs to medicine anaphylactoid reaction sensitive group；If the peripheral blood MRGPRX2 expressing quantities of tester are not more than 14.43ng/mL, it is anti-that it is not belonging to medicine class allergy Answer sensitive group；If the peripheral blood MRGPRX2 expressing quantities of tester are more than 14.43ng/mL, it belongs to medicine class allergy React sensitive group；Wherein, the expression quantity of MRGPRX2 albumen is the ratio of MRGPRX2 albumen qualities and peripheral blood volume in peripheral blood.
- 6. the method for the examination medicine anaphylactoid reaction sensitive group as shown in any one of claim 3~5, it is characterised in that In step 1), the amount of peripheral blood is 1.5~2.0mL.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711130601.4A CN107703312A (en) | 2017-11-15 | 2017-11-15 | The protein marker and method of examination medicine anaphylactoid reaction sensitive group |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711130601.4A CN107703312A (en) | 2017-11-15 | 2017-11-15 | The protein marker and method of examination medicine anaphylactoid reaction sensitive group |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107703312A true CN107703312A (en) | 2018-02-16 |
Family
ID=61179623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711130601.4A Pending CN107703312A (en) | 2017-11-15 | 2017-11-15 | The protein marker and method of examination medicine anaphylactoid reaction sensitive group |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107703312A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110204607A (en) * | 2019-05-31 | 2019-09-06 | 西安交通大学 | A kind of dominant antigen epitope polypeptide of anti-Mrgprx2 antibody and its application |
| CN110204606A (en) * | 2019-05-31 | 2019-09-06 | 西安交通大学 | A kind of polypeptide being used to prepare rabbit polyclonal antibody and its application |
| CN110229227A (en) * | 2019-05-31 | 2019-09-13 | 西安交通大学 | It is a kind of be used to prepare ELISA murine monoclonal coated antibody and rabbit polyclonal detection antibody polypeptide and its application |
| CN110229228A (en) * | 2019-05-31 | 2019-09-13 | 西安交通大学 | The polypeptide with immunogenicity of a kind of pair of anaphylactoid reaction specific receptor MRGPRX2 albumen and its application |
| CN110240643A (en) * | 2019-05-31 | 2019-09-17 | 西安交通大学 | A kind of double antibodies sandwich kit being used to prepare anaphylactoid reaction matches polypeptide and its application of antibody |
| CN111500708A (en) * | 2020-05-08 | 2020-08-07 | 中南大学湘雅医院 | Molecular marker related to narcotic allergy, application thereof and detection kit |
| WO2021201486A1 (en) * | 2020-03-31 | 2021-10-07 | 재단법인 아산사회복지재단 | Method for identifying patient with immediate hypersensitivity reactions by using mrgprx2 |
| CN116855503A (en) * | 2023-08-30 | 2023-10-10 | 上海益诺思生物技术股份有限公司 | Stable transgenic cell strain over-expressing MRGPRX2 and construction method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106754731A (en) * | 2017-02-23 | 2017-05-31 | 西安交通大学 | Recombinant cell and MrgprX2 expression membrane receptor fixing phase and the preparation method and application high of MrgprX2 expression high |
| CN107142325A (en) * | 2017-06-28 | 2017-09-08 | 西安交通大学 | A kind of gene marker and its application for medicine anaphylactoid reaction sensitive group examination |
-
2017
- 2017-11-15 CN CN201711130601.4A patent/CN107703312A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106754731A (en) * | 2017-02-23 | 2017-05-31 | 西安交通大学 | Recombinant cell and MrgprX2 expression membrane receptor fixing phase and the preparation method and application high of MrgprX2 expression high |
| CN107142325A (en) * | 2017-06-28 | 2017-09-08 | 西安交通大学 | A kind of gene marker and its application for medicine anaphylactoid reaction sensitive group examination |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110204607B (en) * | 2019-05-31 | 2021-04-20 | 西安交通大学 | Dominant antigen epitope polypeptide of anti-Mrgprx 2 antibody and application thereof |
| CN110204606A (en) * | 2019-05-31 | 2019-09-06 | 西安交通大学 | A kind of polypeptide being used to prepare rabbit polyclonal antibody and its application |
| CN110229227A (en) * | 2019-05-31 | 2019-09-13 | 西安交通大学 | It is a kind of be used to prepare ELISA murine monoclonal coated antibody and rabbit polyclonal detection antibody polypeptide and its application |
| CN110229228A (en) * | 2019-05-31 | 2019-09-13 | 西安交通大学 | The polypeptide with immunogenicity of a kind of pair of anaphylactoid reaction specific receptor MRGPRX2 albumen and its application |
| CN110240643A (en) * | 2019-05-31 | 2019-09-17 | 西安交通大学 | A kind of double antibodies sandwich kit being used to prepare anaphylactoid reaction matches polypeptide and its application of antibody |
| CN110204607A (en) * | 2019-05-31 | 2019-09-06 | 西安交通大学 | A kind of dominant antigen epitope polypeptide of anti-Mrgprx2 antibody and its application |
| CN110204606B (en) * | 2019-05-31 | 2021-04-20 | 西安交通大学 | Polypeptide for preparing rabbit polyclonal antibody and application thereof |
| WO2021201486A1 (en) * | 2020-03-31 | 2021-10-07 | 재단법인 아산사회복지재단 | Method for identifying patient with immediate hypersensitivity reactions by using mrgprx2 |
| KR20210121802A (en) * | 2020-03-31 | 2021-10-08 | 재단법인 아산사회복지재단 | Method of determining immediate hypersensitivity patients using MRGPRX2 |
| KR102494928B1 (en) * | 2020-03-31 | 2023-02-03 | 재단법인 아산사회복지재단 | Method of determining immediate hypersensitivity patients using MRGPRX2 |
| CN111500708A (en) * | 2020-05-08 | 2020-08-07 | 中南大学湘雅医院 | Molecular marker related to narcotic allergy, application thereof and detection kit |
| CN116855503A (en) * | 2023-08-30 | 2023-10-10 | 上海益诺思生物技术股份有限公司 | Stable transgenic cell strain over-expressing MRGPRX2 and construction method and application thereof |
| CN116855503B (en) * | 2023-08-30 | 2023-12-08 | 上海益诺思生物技术股份有限公司 | Stable transgenic cell strain over-expressing MRGPRX2 and construction method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107703312A (en) | The protein marker and method of examination medicine anaphylactoid reaction sensitive group | |
| Dragoni et al. | Biomarkers of inflammation in inflammatory bowel disease: how long before abandoning single-marker approaches? | |
| Zijlstra | Biomarkers in post-kala-azar dermal leishmaniasis | |
| Habibzadeh et al. | Rate of re-positive RT-PCR test among patients recovered from COVID-19 | |
| CN110272990A (en) | Excretion body microRNA is as depression marker and its application | |
| RU2583939C1 (en) | Method for laboratory diagnosis of stages of hepatic fibrosis in chronic viral hepatitis c | |
| Liu et al. | Consistency and pathophysiological characterization of a rat polymicrobial sepsis model via the improved cecal ligation and puncture surgery | |
| Reis et al. | Biomarkers of pelvic endometriosis | |
| JP2019529959A (en) | Monitoring cancer recurrence and progression | |
| RU2701723C1 (en) | Method of differentiating hepatic fibrosis in chronic viral hepatitis b and autoimmune liver injuries | |
| CN113009158B (en) | Auxiliary diagnostic marker for medium-height myopia and application thereof | |
| US9140712B2 (en) | Immune and oxygen system measuring and drug screening method and apparatus | |
| CN114994327A (en) | Application of biomarker GSDME | |
| US10746722B2 (en) | Method for rapid testing allergy | |
| Muszynska | What is the reason for ambiguous results of magnesium levels in medicine? | |
| Baker et al. | Allosteric antagonist modulation of TRPV2 by piperlongumine impairs glioblastoma progression | |
| CN109342738A (en) | One group of serum differential protein combination is preparing the application in the reagent for detecting Alzheimer's disease | |
| Gidado et al. | Determination of the Relationship Between C-Reactive Protein (CRP) Levels and Hepatitis B Surface Antigen | |
| CN107976543A (en) | A kind of diagnosis kit and detection method | |
| Al-Saffar et al. | P062 Small intestinal lactulose and sucralose hyper-permeability in inflammatory bowel disease | |
| Boraschi et al. | Nano-immunosafety: Issues in assay validation | |
| Tahir et al. | Liver fibrosis and methods of assessment in light of chronic hepatitis delta | |
| Abdulkadhim et al. | The Study of Biomarkers in Patients Who Were Re-Infected With COVID-19 After Being Vaccinated With (Pfizer or Sinopharm) Vaccine in Basra, Iraq | |
| RU83180U1 (en) | ALLERGY DIAGNOSTIC KIT | |
| CN107217055B (en) | A kind of cancer diagnosis chip and its kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180216 |